R&D channel feed – Endpoints News

R&D channel feed

Olema Oncology to cut 25% of staff, says it will focus on late-stage pipeline

3 years ago

AstraZeneca touts PhIII event-free survival win with Imfinzi

3 years ago

Fresh Tracks considers options to stay afloat and develop autoimmune candidates

3 years ago

Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial

3 years ago

Ten years later, Lilly's long-term Alzheimer's trial of solanezumab has definitively failed

3 years ago

ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies

3 years ago

An eye, 15 seconds and striking animation: How Horizon's thyroid eye disease campaign hit home with patients

3 years ago

With PhII fail, Redx Pharma scraps monotherapy biliary cancer development for lead program

3 years ago

Despite mid-stage plaque psoriasis win, J&J appears undecided on PhIII for partner's IL-23 drug

3 years ago

Lenz Therapeutics eyes better vision than AbbVie, Orasis with $80M+ for three PhIII trials

3 years ago

Immuneering cuts neuroscience programs to focus on oncology, extend cash runway

3 years ago

Chiesi puts down $200M+ to collaborate with Affibody for respiratory diseases

3 years ago

Noema Pharma raises $112M Series B to advance CNS disorder pipeline with Roche candidates

3 years ago

Merck unwraps full PhIII data on the centerpiece from its $11.5B Acceleron buyout: #ACC23

3 years ago

Large biopharma companies cull about 40 immuno-oncology programs over the last two quarters

3 years ago

AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps

3 years ago

Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23

3 years ago

With PhII success, BridgeBio wades deeper into dwarfism drug debate

3 years ago

Aclaris shares halved after mid-stage skin disorder fail

3 years ago

Incyte stops PhIII trial for PI3K inhibitor after primary endpoint failure

3 years ago

Cytokinetics' heart drug shows positive results after FDA rejection of earlier treatment: #ACC23

3 years ago

Esperion unveils long-awaited data on cholesterol pill's ability to cut cardiovascular risk: #ACC23

3 years ago

Praxis stock tanks after mid-stage movement disorder trial miss

3 years ago

Roche, Exelixis' Tecentriq/Cabometyx combo flunks second PhIII

3 years ago

First page Previous page 96 97 9899100 101 102 Next page Last page